Histone Deacetylase 6 in Cancer

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2018 Sep 5

PMID 30176876

Citations 127

Authors

Ting Li

Chao Zhang

Shafat Hassan

Xinyue Liu

Fengju Song

Kexin Chen

Wei Zhang

Jilong Yang

Affiliations

Soon will be listed here.

Abstract

Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. Furthermore, HDAC6 also upregulates several critical factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy. Several selective HDAC6 inhibitors are currently in clinical trials for cancer treatment and bring hope for patients with malignant tumors. A fuller understanding of HDAC6 as a critical regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies. Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.

Citing Articles

HDAC6 Facilitates PRV and VSV Infection by Inhibiting Type I Interferon Production.

Zheng H, Yang X, Zhong H, Song C, Wu Z, Yang H Viruses. 2025; 17(1.

PMID: 39861880 PMC: 11768819. DOI: 10.3390/v17010090.

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

Oliveira-Silva J, Oliveira L, Chiminazo C, Fonseca R, Souza C, Aissa A Cancer Chemother Pharmacol. 2025; 95(1):22.

PMID: 39821335 DOI: 10.1007/s00280-024-04731-y.

FSD1 inhibits glioblastoma diffuse infiltration through restriction of HDAC6-mediated microtubule deacetylation.

Xiao D, Ran H, Chen L, Li Y, Cai Y, Zhang S Sci China Life Sci. 2025; 68(3):673-688.

PMID: 39808222 DOI: 10.1007/s11427-024-2616-7.

Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article.

Wagih N, Abdel-Rahman I, El-Koussi N, Abuo-Rahma G RSC Adv. 2025; 15(2):966-1010.

PMID: 39807197 PMC: 11726184. DOI: 10.1039/d4ra05014b.

Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.

de Bakker T, Maes A, Dragan T, Martinive P, Penninckx S, Van Gestel D Cells. 2025; 14(1.

PMID: 39791719 PMC: 11719474. DOI: 10.3390/cells14010018.

References

Olsen E, Kim Y, Kuzel T, Pacheco T, Foss F, Parker S . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(21):3109-15. DOI: 10.1200/JCO.2006.10.2434. View

Li D, Sun X, Zhang L, Yan B, Xie S, Liu R . Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Protein Cell. 2014; 5(3):214-23. PMC: 3967059. DOI: 10.1007/s13238-013-0010-3. View

Tan J, Cang S, Ma Y, Petrillo R, Liu D . Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010; 3:5. PMC: 2827364. DOI: 10.1186/1756-8722-3-5. View

Koeneke E, Witt O, Oehme I . HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities. Cells. 2015; 4(2):135-68. PMC: 4493453. DOI: 10.3390/cells4020135. View

Hao M, Song F, Du X, Wang G, Yang Y, Chen K . Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Lett. 2015; 359(1):1-8. DOI: 10.1016/j.canlet.2014.12.050. View

Richardson P, Schlossman R, Alsina M, Weber D, Coutre S, Gasparetto C . PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122(14):2331-7. DOI: 10.1182/blood-2013-01-481325. View

Schroeder T, Rautenberg C, Haas R, Kobbe G . Hypomethylating agents after allogeneic blood stem cell transplantation. Stem Cell Investig. 2017; 3:84. PMC: 5182210. DOI: 10.21037/sci.2016.11.04. View

Verdin E, Dequiedt F, Kasler H . Class II histone deacetylases: versatile regulators. Trends Genet. 2003; 19(5):286-93. DOI: 10.1016/S0168-9525(03)00073-8. View

Lafarga V, Aymerich I, Tapia O, Mayor Jr F, Penela P . A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J. 2011; 31(4):856-69. PMC: 3280560. DOI: 10.1038/emboj.2011.466. View

10.

Amengual J, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G . Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res. 2015; 21(20):4663-75. PMC: 4609274. DOI: 10.1158/1078-0432.CCR-14-3068. View

11.

Boyault C, Sadoul K, Pabion M, Khochbin S . HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007; 26(37):5468-76. DOI: 10.1038/sj.onc.1210614. View

12.

Blee A, Liu S, Wang L, Huang H . BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget. 2016; 7(25):38319-38332. PMC: 5122392. DOI: 10.18632/oncotarget.9513. View

13.

Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N . Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget. 2016; 8(5):7572-7585. PMC: 5352344. DOI: 10.18632/oncotarget.13810. View

14.

Nakashima H, Kaufmann J, Wang P, Nguyen T, Speranza M, Kasai K . Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest. 2015; 125(11):4269-80. PMC: 4639993. DOI: 10.1172/JCI80713. View

15.

Richardson P, Moreau P, Laubach J, Maglio M, Lonial S, San-Miguel J . Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res. 2016; 117:185-191. DOI: 10.1016/j.phrs.2016.11.020. View

16.

de Ruijter A, van Gennip A, Caron H, Kemp S, van Kuilenburg A . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2002; 370(Pt 3):737-49. PMC: 1223209. DOI: 10.1042/BJ20021321. View

17.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

18.

Liu W, Fan L, Zhou X, Sweeney Jr W, Avner E, Li X . HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012; 7(11):e49418. PMC: 3496684. DOI: 10.1371/journal.pone.0049418. View

19.

Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

20.

Woan K, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T . Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015; 9(7):1447-1457. PMC: 4523430. DOI: 10.1016/j.molonc.2015.04.002. View